IP Library Granted Patent US 8,999,397
Granted Patent B2
US 8,999,397 · App. 13/861,688 · Granted Apr 7, 2015

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Inventors: Patrick M. Hughes (Aliso Viejo, CA); Michele Boix (Cantaron, FR); Christian Sarrazin (Pegomas, FR); Marina Do (Menton, FR)
Assignee: Allergan, Inc.
A61K9/0048A61K9/0051A61K47/34B01J13/04B01J13/06A61K31/165A61K31/216
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,397
App. No.
13/861,688
Granted
Apr 7, 2015
Kind
B2
Abstract

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Claims (7)

1. A population of microparticles comprising a polymeric component encapsulating a prostamide component in the form of oil-in-oil emulsified microparticles having a maximum particle diameter less than about 200 μm, wherein the prostamide component comprises bimatoprost, a combination of bimatoprost and latanoprost, or a combination of bimatoprost and travoprost.

2. The population of claim 1 , wherein the polymeric component comprises a poly(lactide-co-glycolide) copolymer.

3. The population of claim 1 which is terminally sterilized.

4. The population of claim 3 , wherein at least 80% of the prostamide component remains stable after the sterilization.

5. The population of claim 1 having a mean particle diameter from about 30 μm to about 50 μm.

6. The population of claim 1 , wherein the prostamide component comprises about 10% wt/wt of the microparticles.

7. The population of claim 1 , wherein the prostamide component comprises about 5% wt/wt of the microparticles.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2015
From: HUGHES, PATRICK M.; BOIX, MICHELE; SARRAZIN, CHRISTIAN; DO, MARINA
To: ALLERGAN, INC.
Reel/Frame 034728/0969 →
Continuity (4)
Continuation 13152780 · Jun 3, 2011
Division 11303462 · Dec 15, 2005
Continuation In Part 10837260 · Apr 30, 2004
Related Publication 20130236557A1 · Sep 12, 2013